Molecular Instruments targets a major multiplex IF bottleneck with automated HCR Gold IF on BOND RX
Discover how HCR Gold IF on BOND RX could streamline multiplex tissue research, preserve antibody workflows and reshape spatial biology.
Medical Devices & Diagnostics
Pharma & Biotech
Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.
Medical Devices & Diagnostics
Why PreludeDx’s second FDA breakthrough device designation matters for precision diagnostics
Breast cancer care needs sharper radiation decisions. PreludeDx’s AidaBREAST now faces the harder test of validation, adoption and access.
Pharma & Biotech
Takara Bio USA unveils AACR benchmark data for Trekker FX, but will cancer labs switch?
Takara Bio USA says Trekker FX outperformed conventional spatial methods in a cancer benchmark study. Read what this could mean for oncology research.
Medical Devices & Diagnostics
Why 10x Genomics is betting on peripheral blood to decode complex immune disorders
Find out how 10x Genomics and Brigham & Women's Hospital are using single-cell profiling to redefine autoimmune diagnostics. Can it change patient care?
Medical Devices & Diagnostics
How AidaBreast’s multi-omic insights may reduce overtreatment in breast cancer care
Prelude Corporation has announced the first independent validation of AidaBreast, a multi-omic diagnostic test developed to predict both locoregional recurrence risk and individualized radiation therapy benefit in early-stage hormone receptor-positive, HER2-negative invasive breast cancer. The study, conducted at Royal Melbourne Hospital and presented at the San Antonio Breast Cancer Symposium 2025, evaluated over 400 women